BiotechTube

RG2133 (2',3',5'-tri-O-acetyluridine)

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mitochondrial Diseases

Conditions

Mitochondrial Diseases

Trial Timeline

— → —

NCT ID
NCT00060515

About RG2133 (2',3',5'-tri-O-acetyluridine)

RG2133 (2',3',5'-tri-O-acetyluridine) is a phase 1 stage product being developed by Repligen for Mitochondrial Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT00060515. Target conditions include Mitochondrial Diseases.

What happened to similar drugs?

0 of 1 similar drugs in Mitochondrial Diseases were approved

Approved (0) Terminated (0) Active (1)
🔄VatiquinonePTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00060515Phase 1Terminated

Competing Products

13 competing products in Mitochondrial Diseases

See all competitors
ProductCompanyStageHype Score
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mgAbbViePhase 2
35
Cysteamine BitartrateAmgenPhase 2
27
Cysteamine BitartrateAmgenPhase 2
35
VatiquinonePTC TherapeuticsPhase 2/3
27
EPI-743PTC TherapeuticsPre-clinical
23
VatiquinonePTC TherapeuticsPre-clinical
27
VatiquinonePTC TherapeuticsPhase 3
37
Oral administration of 100 mg KH176 twice dailyCertaraPhase 2
29
Sonlicromanol + PlaceboCertaraPhase 2
33